𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates

✍ Scribed by P. J. Blanchet; R. Grondin; Dr. P. J. Bédard

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
563 KB
Volume
11
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The motor effects of the short‐acting, full D~1~ agonist SKF 82958 were studied in three drug‐naive, 1‐methyl‐4‐phenyl‐1, 2, 3, 6‐tetrahydropyridine‐lesioned, parkinsonian monkeys treated for 4 weeks. D~1~ receptor stimulation with SKF 82958 effectively relieved parkinsonism but induced choreic dyskinesia (n = 2) and a shorter duration of motor benefit (n = 3) over time. Isolated, short‐lived D~1~ receptor activation would not appear to confer advantage over levodopa for dyskinesia prevention. Our data also support the involvement of postsynaptic dopamine receptor mechanisms in the wearing‐off phenomenon seen in levodopa‐treated parkinsonian patients.

📜 SIMILAR VOLUMES

The dopamine D1 agonist SKF 81297 and th
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys
✍ R. J. Vermeulen; Dr. B. Drukarch; M. C. R. Sahadat; C. Goosen; E. C. Wolters; J. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 902 KB

## Abstract At present, the pharmacotherapy of Parkinson's disease (PD) consists mainly of L‐dihydroxyphenylalanine (L‐DOPA) and/or dopamine D~2~ receptor agonist. However, in general the clinical efficacy of D~2~ agonists is less than that of L‐DOPA. Therefore, attention is being focussed on the r

Behavioral motor recovery in the 1-methy
Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): Changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins
✍ Giselle M. Petzinger; Beth Fisher; Elizabeth Hogg; Avery Abernathy; Pablo Areval 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 931 KB

## Abstract The neurotoxicant 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) provides an excellent opportunity to study repair and response to injury in the basal ganglia. Administration to mammals leads to the destruction of nigrostriatal dopaminergic neurons and depletion of striatal dopamin